Daniel Zingg
8PUBLICATIONS
94CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Dec 29, 2025
C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3.Julia Yemelyanenko, Jinhyuk Bhin, Eline van der Burg
|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Dejan Juric, Kyung Song, Radia M Johnson
|Jun 24, 2025
The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.Daniel Zingg, Chi-Chuan Lin, Julia Yemelyanenko
|Aug 29, 2023
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.Jinhyuk Bhin, Julia Yemelyanenko, Xue Chao
|Sep 01, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko
|Aug 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko
Pageof 2
Frequent Collaborators
6 joint publications
Sjoerd Klarenbeek
6 joint publications
Lodewyk F A Wessels
6 joint publications
Jos Jonkers
5 joint publications
Jinhyuk Bhin
5 joint publications
Julia Yemelyanenko
3 joint publications
Bjørn Siteur
3 joint publications
Stefano Annunziato
3 joint publications
Jessica K Lee
3 joint publications
Marieke van de Ven
2 joint publications
Chang S Chan
